Price:
Rs. 60,000.00
Sample Type: EDTA Whole Blood
Fasting Not Required
Notes:N8192
Frequently Asked Questions (FAQ's):
What does the NextGen GeneCore Immunotherapy Panel (TMB + MSI + PD-L1 SP263) at Metropolis Healthcare include?
It evaluates TMB, MSI status, and PD-L1 expression using the SP263 clone to guide immunotherapy decisions.
How does Metropolis Healthcare perform this immunotherapy panel?
Metropolis Healthcare uses deep NGS for TMB/MSI analysis and validated SP263 immunohistochemistry for PD-L1 scoring.
Who should consider this test at Metropolis Healthcare?
Patients with solid tumors being evaluated for immune checkpoint inhibitor therapy should undergo this panel.
Is fasting required for this immunotherapy panel at Metropolis Healthcare?
No, fasting is not required; the test is performed on tumor tissue and/or blood as advised.
How long do results take at Metropolis Healthcare?
Results typically take 2–3 weeks, allowing time for comprehensive genomic and IHC analysis.
Can this test at Metropolis Healthcare help select the right immunotherapy?
Yes, it identifies biomarkers that help predict response to PD-1/PD-L1 inhibitors and related treatments.
How accurate is the PD-L1 SP263 method used by Metropolis Healthcare?
Metropolis Healthcare uses validated SP263 assays known for high analytical accuracy and clinically reliable scoring.
Can this panel assist in long-term treatment planning at Metropolis Healthcare?
Yes, combined insights from TMB, MSI, and PD-L1 SP263 support personalized treatment strategies and prognosis assessment.